POWERED BY

TP-102 demonstrates favorable safety profile in one of the largest controlled bacteriophage therapy studies to date

PublishedNovember 22, 2026

Portugal’s Technophage has announced the results from its Phase 2b REVERSE 2 clinical trial evaluating TP-102, an investigational bacteriophage therapy for the treatment of Diabetic Foot Infections caused by Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii.

The REVERSE 2 study represents an important milestone not only for TP-102, but also for the broader field of bacteriophage therapy. The study adds valuable clinical evidence supporting the safety of bacteriophage-based medicines and has provided important insights into the patient populations most likely to benefit from this therapeutic approach.

Miguel Garcia, CEO of Technophage.

REVERSE 2 represents one of the largest randomized, placebo-controlled clinical studies conducted in bacteriophage therapy to date, contributing with important clinical evidence to a field with significant potential to address difficult-to-treat bacterial infections. The multicenter Phase 2b study evaluated TP-102 in patients receiving Standard of Care treatment and further expanded the clinical experience with bacteriophage-based therapeutics.

Overall, TP-102 demonstrated a favorable safety and tolerability profile, with no treatment-related safety findings observed during the study. These results further strengthen the growing body of evidence supporting the safety of bacteriophage therapy in clinical settings.

Exploratory analyses also identified a clinically meaningful efficacy signal in a specific patient subpopulation. The observed treatment effect increased progressively among patients presenting characteristics associated with more severe and active infection at baseline, including purulent wounds and higher Diabetic Foot Ulcer Wound Infection (DFUWI) scores. These findings suggest that patient selection based on infection characteristics may be important for maximizing the therapeutic benefit and support further prospective evaluation of an enrichment strategy.

Technophage intends to discuss the REVERSE 2 findings with regulatory authorities to obtain guidance on the most appropriate development pathway for TP-102. These discussions will help inform the design of future clinical studies aimed at prospectively evaluating TP-102 in patient populations enriched for the characteristics associated with the efficacy signals observed in REVERSE 2.

Source